Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of PA21 vs sevelamer in hyperphosphatemia on hemodialysis
2008-004748-36Phase 2Completed
- Sponsor
- CSL Vifor
- Start
- Oct 2008
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Sucroferric oxyhydroxide in hyperphosphatemia (2 arms), sponsored by CSL Vifor. Primary endpoint: Change from baseline in serum phosphate at end of treatment. Started Oct 2008; status: completed.
02
Drugs
Sucroferric oxyhydroxide
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on 2008-004748-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004748-36.